Insights
Search Results
7.29.24
Firm Advises Nerio on IP Matters Related to $1.3 Billion Acquisition by Boehringer
On July 29, 2024, biopharmaceutical company Boehringer Ingelheim announced its acquisition of Nerio Therapeutics, a drug discovery and development company focused on phosphatases, a notoriously difficult class of potentially high-value therapeutic protein targets, and its preclinical program of novel immune checkpoint inhibitors for up to $1.3 billion. Wilson Sonsini Goodrich & Rosati advised Nerio Therapeutics on IP related to the transaction and advises the company on patent matters.
Client Highlights
5.01.24
Wilson Sonsini Advises Enlaza Therapeutics on IP Matters Related to $100 Million Series A
On April 30, 2024, Enlaza Therapeutics (Enlaza), the first covalent biologic platform company, announced it successfully closed a $100 million Series A financing. The round was led by the Life Sciences group of J.P. Morgan Asset Management’s Private Capital division, with participation from existing investors Frazier Life Sciences, Avalon Ventures, Lightspeed Venture Partners, and Samsara BioCapital. The financing also includes new investors Amgen Ventures, Regeneron Ventures, Bregua Corporation, Pappas Capital, and Alexandria Venture Investments. Wilson Sonsini Goodrich & Rosati advised Enlaza on IP matters related to the Series A and represents the company in patent strategy and prosecution matters.
Client Highlights
4.11.24
Wilson Sonsini Advises Boundless Bio on IP Matters Related to IPO
On March 27, 2024, Boundless Bio, a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, announced the pricing of its initial public offering of 6,250,000 shares of its common stock at an initial public offering price of $16.00 per share. All of the shares were offered by Boundless Bio. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $100.0 million. Boundless Bio’s common stock began trading on the Nasdaq Global Select Market on March 28, 2024, under the ticker symbol “BOLD," and closed on April 2, 2024. In addition, Boundless Bio has granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
Client Highlights
4.03.24
Wilson Sonsini Advises Alterome on $132 Million Series B
On April 3, 2024, Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, announced the closing of a $132 million Series B financing. The financing was led by Goldman Sachs Alternatives, with participation by Canaan Partners, Invus, Driehaus Capital Management, Digitalis Ventures, Blue Owl Capital, and existing investors Orbimed, Nextech Invest, Vida Ventures, Boxer Capital, and Colt Ventures. Wilson Sonsini Goodrich & Rosati advised Alterome on the transaction.
Client Highlights
2.20.24
Wilson Sonsini Advises Kinnate Biopharma on Acquisition By XOMA
On February 16, 2024, Kinnate Biopharma Inc., a clinical-stage precision oncology company, announced it has entered into a definitive merger agreement whereby XOMA Corporation will acquire Kinnate. Pursuant and subject to the terms of the merger agreement, a wholly owned subsidiary of XOMA will commence a tender offer by March 4, 2024 to acquire all outstanding shares of Kinnate common stock. The merger transaction is expected to close in the first half of 2024. Wilson Sonsini Goodrich & Rosati is advising Kinnate on the transaction.
Client Highlights
12.22.23
Wilson Sonsini Advises K18 on Intellectual Property, Licensing, and Corporate Matters Related to Acquisition by Unilever
On December 22, 2023, Unilever, announced that it has entered into a definitive agreement to acquire premium biotech haircare brand K18. Wilson Sonsini Goodrich & Rosati is advising K18 on intellectual property, licensing, and corporate matters related to the transaction.
Client Highlights
11.09.23
Wilson Sonsini Advises Forward Therapeutics on IP Matters Related to $50M Series A Financing
On November 8, 2023, Forward Therapeutics, a biopharmaceutical company developing small molecule therapies for chronic immunological and inflammatory disorders, announced that it raised $50 million in Series A funding. Wilson Sonsini Goodrich & Rosati advised Forward Therapeutics on IP matters related to the transaction.
Client Highlights
5.16.23
Firm Advises Boundless Bio on IP Matters Related to $100 Million Series C
On May 16, 2023, Boundless Bio, a clinical-stage, next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) for patients with oncogene amplified cancers, announced the closing of a $100 million Series C financing. The financing was co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and RA Capital Management, with participation from additional new investors Sectoral Asset Management and Piper Heartland Healthcare Capital. Wilson Sonsini Goodrich & Rosati advised Boundless Bio on IP matters related to the transaction.
Press Releases
12.05.22
Wilson Sonsini Goodrich & Rosati Elects 18 New Partners
Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, today announced that the firm has elected 18 new partners from its attorney ranks. The promotions will be effective February 1, 2023.
Client Highlights
9.26.22
Wilson Sonsini Advises RA Capital Management on Rivus Pharmaceuticals' $132 Million Series B
On September 22, 2022, Rivus Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to improving cardio-metabolic health, announced the completion of a $132 million Series B financing led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG, and existing investors Longitude Capital, Medicxi, and RxCapital. Wilson Sonsini Goodrich & Rosati advised RA Capital in the transaction.
Alerts
8.25.22
Duties of Disclosure and Reasonable Inquiry Before the USPTO May Include Communications with the FDA and Other Government Agencies
Spurred by President Biden's call for action to increase drug competition and a 2021 letter addressed to the U.S. Patent and Trademark Office (USPTO) by Senators Leahy and Tillis requesting the USPTO "to take action to require applicants to disclose relevant statements they have made to other agencies relating to inventions discussed in their patent applications or about prior art that is being applied in the patent examination process,"1 the USPTO recently issued a Notice2 that clarifies the duties of disclosure and reasonable inquiry, which can concern information submitted to the U.S. Food and Drug Administration (FDA) and other government agencies that are material to the patentability of a claimed invention.